GlassScriptPhysician profile
Julie Singh
NPI 1669912374
$4,627.13
in general payments reported to CMS, 2019-2025
42 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $125 · 2021: $132 · 2022: $75.53 · 2023: $581 · 2024: $1,609 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.48 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $610.81 | 2023-2025 | |
| Lilly USA, LLC | $609.12 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $579.93 | 2021-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $276.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $258.79 | 2023-2025 | Minimed 780g |
| Abbvie INC. | $222.58 | 2023-2025 | Mavyret, Synthroid |
| Glaxosmithkline, LLC. | $213.39 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $150.84 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $147.64 | 2023-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $126.88 | 2022-2025 | |
| Esperion Therapeutics, INC. | $124.69 | 2020 | |
| Genentech USA, INC. | $122.14 | 2019 | |
| Ucb, INC. | $112.26 | 2023-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $105.77 | 2024-2025 | Tymlos |
| Pfizer INC. | $103.19 | 2019 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $73.91 | 2024-2025 | Tremfya, Simponi Aria |
| Insulet Corporation | $69.27 | 2024-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.39 | 2022-2025 | Jardiance, Synjardy |
| Ibsa Pharma INC. | $60.56 | 2023-2024 | Tirosint, Tirosint, Licart |
| Dexcom, INC. | $57.61 | 2023-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $51.13 | 2021-2025 | Korlym |
| Ascensia Diabetes Care US INC. | $47.74 | 2025 | |
| Ascendis Pharma Endocrinology INC | $37.04 | 2025 | Yorvipath |
| Exact Sciences Corporation | $34.59 | 2025 | Cologuard Collection Kit |
| Amphastar Pharmaceuticals, INC. | $34.33 | 2025 | |
| Tolmar, INC. | $30.45 | 2024 | |
| Aurinia Pharma U.S., INC. | $23.80 | 2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $20.36 | 2025 | Acthar |
| Abbott Laboratories | $19.24 | 2023 | Freestyle Libre 3 |
| Octapharma USA, INC. | $18.20 | 2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $17.37 | 2024 | Strensiq |
| Recordati_rare_diseases_inc. | $16.71 | 2024 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $16.53 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $16.39 | 2023 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.30 | 2024 | Trulance, Xifaxan |
| Amneal Pharmaceuticals LLC | $16.25 | 2025 | Unithroid |
| Currax Pharmaceuticals LLC | $16.18 | 2024 | Contrave |
| Kiniksa Pharmaceuticals International, Plc | $16.07 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $15.73 | 2024 | |
| Invivyd INC | $15.71 | 2025 | Pemgarda |
| Sequel Med Tech, LLC | $14.91 | 2025 | Twiist |
| Sobi, INC | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.